Anxiety disorders, PTSD and OCD: systematic review of approved psychiatric medications (2008–2024) and pipeline phase III medications

Emile Tadros, Shirley Keerthana, Samar Padder, Jayant Totlani, Drew Hirsch, Daniel N Kaidbay, Lorena Contreras, Aasim Naqvi, Samuel Miles, Krista Mercado, Ashley Meyer, Sabrina Renteria, Robert N Pechnick, Itai Danovitch, Waguih William IsHak

Article Type

Review

Published

By examining the mechanisms of action, indications, efficacy, dosing and adverse effects of psychiatic medications approved by the FDA, this review seeks to evaluate the progress and future directions in the pharmacological treatment of post-traumatic stress disorder and obsessive-compulsive
disorder.

Read more

Register for alerts

I would like to be contacted by Drugs in Context when new articles are posted.